Unknown

Dataset Information

0

BC-N102 suppress breast cancer tumorigenesis by interfering with cell cycle regulatory proteins and hormonal signaling, and induction of time-course arrest of cell cycle at G1/G0 phase.


ABSTRACT: Mechanisms of breast cancer progression and invasion, often involve alteration of hormonal signaling, and upregulation and/or activation of signal transduction pathways that input to cell cycle regulation. Herein, we describe a rationally designed first-in-class novel small molecule inhibitor for targeting oncogenic and hormonal signaling in ER-positive breast cancer. BC-N102 treatment exhibits dose-dependent cytotoxic effects against ER+ breast cancer cell lines. BC-N102 exhibited time course- and dose-dependent cell cycle arrest via downregulation of the estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), phosphatidylinositol 3-kinase (PI3K), phosphorylated (p)-extracellular signal-regulated kinase (ERK), p-Akt, CDK2, and CDK4 while increasing p38 mitogen-activated protein kinase (MAPK), and mineralocorticoid receptor (MR) signaling in breast cancer cell line. In addition, we found that BC-N102 suppressed breast cancer tumorigenesis in vivo and prolonged the survival of animals. Our results suggest that the proper application of BC-N102 may be a beneficial chemotherapeutic strategy for ER+ breast cancer patients.

SUBMITTER: Lawal B 

PROVIDER: S-EPMC8375223 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

BC-N102 suppress breast cancer tumorigenesis by interfering with cell cycle regulatory proteins and hormonal signaling, and induction of time-course arrest of cell cycle at G1/G0 phase.

Lawal Bashir B   Kuo Yu-Cheng YC   Wu Alexander T H ATH   Huang Hsu-Shan HS  

International journal of biological sciences 20210725 12


Mechanisms of breast cancer progression and invasion, often involve alteration of hormonal signaling, and upregulation and/or activation of signal transduction pathways that input to cell cycle regulation<b>.</b> Herein, we describe a rationally designed first-in-class novel small molecule inhibitor for targeting oncogenic and hormonal signaling in ER-positive breast cancer. BC-N102 treatment exhibits dose-dependent cytotoxic effects against ER+ breast cancer cell lines. BC-N102 exhibited time c  ...[more]

Similar Datasets

| S-EPMC4442456 | biostudies-literature
| S-EPMC6593979 | biostudies-literature
| S-EPMC4233052 | biostudies-literature
| S-EPMC9251049 | biostudies-literature
| S-EPMC6566573 | biostudies-literature
| S-EPMC11296530 | biostudies-literature
| S-EPMC7114671 | biostudies-literature
| S-EPMC11638257 | biostudies-literature
| S-EPMC8908156 | biostudies-literature
| S-EPMC7901084 | biostudies-literature